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The ﬁrst UPLC method for simultaneous determination of empagliﬂozin, linagliptin and metformin
hydrochloride in the diﬀerent combinations of their pharmaceutical dosage forms was developed.
Chromatographic separation was achieved on a Symmetry® Acclaim™ RSLC 120 C18 column (100 mm
 2.1 mm, 2.2 mm) applying isocratic elution based on potassium dihydrogen phosphate buﬀer pH (4)–
methanol (50 : 50, v/v) as the mobile phase. The linearity, accuracy and precision were found to be
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acceptable over the concentration ranges of 1–32 mg mL1, 0.5–16 mg mL1 and 1–100 mg mL1 for

DOI: 10.1039/c5ra17231d

optimize the chromatographic conditions. The optimized method was validated and proved to be
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suitable for the quality control of the mentioned drugs in their diﬀerent pharmaceutical dosage forms.

empagliﬂozin, linagliptin and metformin hydrochloride, respectively. All the variables were studied to

1. Introduction
Empagliozin (EGN), (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)oxolan-3-yl]oxyphenyl]methyl] phenyl]-6-(hydroxymethyl)oxane3,4,5-triol (Fig. 1(a)), is an inhibitor of sodium glucose cotransporter-2 (SGLT-2), which accounts for about 90 percent
of glucose reabsorption into the blood.1 Linagliptin (LGP),
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4methylquinazolin-2-yl) methyl]-3,7-dihydro-1H-purine-2,6-dione
(Fig. 1(b)), belongs to a dipeptidyl-peptidase-4 inhibitor class
which stimulates glucose-dependent insulin release.2 Metformin hydrochloride (MET), N,N-dimethylimidodicarbonimidic
diamide (Fig. 1(c)), is a biguanide hypoglycemic drug that
exerts its eﬀect mainly by increasing peripheral utilization of
glucose.3
To the best of the author’s knowledge, no published
methods are available for the determination of EGN either
alone or as part of a combination in pharmaceutical dosage
forms. A literature review showed that few methods have been
described for the determination of LGP in pharmaceutical
preparations including spectrophotometry and chromatographic methods.4–9 In addition, numerous analytical methods
have been reported for the determination of MET in pharmaceutical preparations including spectrophotometry and chromatographic methods.10–25
The aim of the new proposed UPLC method is to present the
rst method for simultaneous determination of EGN, LGP and
MET, in bulk and in the diﬀerent combinations of their
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pharmaceutical dosage forms. Furthermore, it is the rst
method for determination of empagliozin either alone or as
part of a combination. In addition, the established UPLC
method has many advantages over the routine HPLC methods
reported for LGP and MET as UPLC is more economic,
consuming less organic solvent and less time. Finally, the newly
developed UPLC method has major advantages in comparison
to the reported methods for LGP and MET,4–25 including
simultaneous determination of EMP with LGP and MET,
reduced retention times, enhanced resolution, better sensitivity

Fig. 1 Chemical structures of empagliﬂozin (a), linagliptin (b) and
metformin (c).
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System suitability tests for the proposed UPLC methoda

Item

MET

LGP

EGN

N
T
R
%RSD for 6 injections (peak area)
%RSD for 6 injections (retention time)

1584
1.02

2614
1.01

2874
1.00

a

2.08
0.21
0.15

0.19
0.33

N: number of theoretical plates, T: tailing factor, R: resolution between two consecutive peaks, %RSD: percentage relative standard deviation.

and a simple mobile phase. Most of the advantages may be
attributed to moving from HPLC to UPLC.
Published on 20 October 2015. Downloaded on 7/30/2020 8:42:50 PM.

4.81

0.32
0.18

2.

Experimental

2.1. Instrumentation
The liquid chromatography system consisted of a Thermo Fisher
UPLC SYSTEM Model Ultimate 3000 Complete Ultra High
Performance Liquid Chromatography (USA). For the UPLC
system, a Symmetry® Acclaim™ RSLC 120 C18 column (100 mm
 2.1 mm, 2.2 mm) (USA) was used. The system was equipped
with a diode array detector (DAD-3000RS, USA) and an autosampler (WPS-3000TRS, Thermo scientic, USA). An Elmasonic S
60 H (Germany) was used for the degassing of the mobile phases.
A Jenway digital pH meter was used to adjust and determine the
hydrogen ion concentration (pH) of the buﬀer solutions.
2.2. Reagents and reference samples
Pharmaceutical grade EGN and LGP certied to contain 99.70%
and 99.90% of the drugs, respectively; Jardiance® tablets
nominally containing 25 mg of EGN per tablet; Tradjenta®
tablets nominally containing 5 mg of LGP per tablet;
Jentadueto® tablets nominally containing 2.5 mg of LGP and
500 mg of metformin hydrochloride per tablet; Synjardy®
tablets nominally containing 12.5 mg of EGN and 850 mg of
MET per tablet; and Glyxambi® tablets nominally containing 5
mg of linagliptin and 10 mg of empagliozin per tablet were
supplied by Boehringer Ingelheim pharmaceutical company

Table 2

(Germany). Metformin hydrochloride, certied to contain
99.80% of the drug, was supplied by Chemical Industries
Development (CID) Co., (Giza, Egypt). Glucophage® tablets
nominally containing 500 mg metformin per tablet were
supplied by Merck Serono (Egypt).
HPLC grade methanol was purchased from Fisher Scientic
(Loughborough, Leicestershire, UK). Orthophosphoric acid
(85%) was purchased from VWR Chemicals (Pool, England).
HPLC grade potassium dihydrogen phosphate was purchased
from Sigma Aldrich (Deisenhofen, Germany). Bi-distilled water
was produced in-house (POLNA, DE 10, Poland). PTFE
membrane lters, 47 mm, 0.20 mm (100/pk), (UK) were used. All
other chemicals and reagents used were of analytical grade
unless indicated otherwise.
2.3. Standard stock solutions
Standard stock solutions of EGN, LGP & MET (1 mg mL1) were
prepared by dissolving 100 mg of the drug in methanol using
a 100 mL volumetric ask and completing to volume with
methanol. The mixture was sonicated for ten minutes and then
the required concentrations were prepared by serial dilution
using the mobile phase.
2.4. Working solutions
A working solution of EGN (40 mg mL1) was prepared by dilution of 4 mL of its stock solution in a 100 mL volumetric ask by
completing to volume with the mobile phase. A working solution of LGP (20 mg mL1) was prepared by dilution of 2 mL of its

Results obtained using the proposed UPLC method for simultaneous determination of EGN, LGP and MET

Item

MET

LGP

EGN

UPLC-UV detection
Retention time
Linearity
Regression equation
Regression coeﬃcient (r2)
Standard deviation of slope
Standard deviation of intercept
Accuracy (mean  SD)
Dosage form (mean  SD)
Drug added (standard addition)
LOD
LOQ
Intraday %RSD
Interday %RSD

225 nm
1.6
1–100 mg mL1
AUP ¼ 1.3213Cmg
1
0.012
0.03
100.65  1.18
99.28  0.77
99.38  0.86
0.21 mg mL1
0.63 mg mL1
0.16–0.27
0.12–0.30

225 nm
2.3
0.5–16 mg mL1
AUP ¼ 3.4148Cmg
0.9998
0.026
0.08
98.88  1.06
99.62  1.16
98.64  0.83
0.12 mg mL1
0.36 mg mL1
0.22–0.34
0.10–0.26

225 nm
4.7
1–32 mg mL1
AUP ¼ 4.7462Cmg
0.9999
0.035
0.05
99.81  0.90
99.25  1.23
100.59  1.33
0.26 mg mL1
0.78 mg mL1
0.19–0.28
0.14–0.31
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mL1

+ 0.128

mL1

+ 0.0301

mL1

+ 0.0481
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(A) UPLC chromatogram of a laboratory prepared mixture of (a) metformin hydrochloride (20 mg mL1), (b) linagliptin (1.5 mg mL1) and (c)
empagliﬂozin (1.5 mg mL1). (B) UPLC chromatogram of the Jentadueto® tablet extract in methanol containing (a) metformin hydrochloride (100
mg mL1) and (b) linagliptin (0.5 mg mL1). (C) UPLC chromatogram of the Synjardy® tablet extract in methanol containing (a) metformin
hydrochloride (68 mg mL1) and (b) empagliﬂozin (1 mg mL1). (D) UPLC chromatogram of the Glyxambi® tablet extract in methanol containing (a)
linagliptin (2.5 mg mL1) and (b) empagliﬂozin (5 mg mL1).
Fig. 2

stock solution in a 100 mL volumetric ask by completing to
volume with the mobile phase. While the working solution of
MET (100 mg mL1) was prepared by dilution of 10 mL of its
stock solution in a 100 mL volumetric ask by completing to
volume with the mobile phase.
2.5. Chromatographic conditions
Chromatographic separation was achieved on a Symmetry®
Acclaim™ RSLC 120 C18 column (100 mm  2.1 mm, 2.2 mm)
applying isocratic elution based on potassium dihydrogen
phosphate buﬀer pH (4)–methanol (50 : 50, v/v) as the mobile
phase. The ultraviolet detector was operated at 225 nm. The
buﬀer solution was ltered through a 0.2 mm membrane lter
and degassed for 30 min in an ultrasonic bath prior to use. The
mobile phase was pumped through the column at a ow rate of
0.4 mL min1. The column temperature was adjusted to 50  C
and the injection volume was 10 mL.
2.6. Sample preparation
Twenty tablets of Jardiance®, Tradjenta®, Glucophage®,
Jentadueto®, Synjardy® and Glyxambi® were separately

This journal is © The Royal Society of Chemistry 2015

weighed, powdered and mixed in a mortar. Accurately weighed
amounts of the nely powdered Jardiance®, Tradjenta® and
Glucophage® tablets, equivalent to 10 mg of EGN, LGP and
MET, respectively, were separately made up to 100 mL with
methanol and sonicated to dissolve them. Also accurately
weighed amounts of the nely powdered Jentadueto® tablets
equivalent to 0.5 mg of LGP and 100 mg of MET, Synjardy®
tablets equivalent to 1 mg of EGN and 68 mg of MET, and
Glyxambi® tablets equivalent to 2.5 mg of EGN and 5 mg of LGP
were separately made up to 100 mL with methanol and sonicated to dissolve them. The solutions were ltered, followed by
serial dilution to the required concentrations using the mobile
phase for each experiment and inclusion of the necessary
amount of drug for the standard addition technique.
2.7. Procedure
2.7.1. Linearity. Accurately measured aliquots of the stock
solutions equivalent to 10–320 mg, 5–160 mg and 10–1000 mg for
EGN, LGP and MET, respectively, were transferred separately
into a series of 10 mL volumetric asks, completed to volume
with the mobile phase, transferred into the vials of the auto

RSC Adv., 2015, 5, 95703–95709 | 95705
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Fig. 3 (a) UPLC chromatogram of the Jardiance® tablet extract in methanol containing empagliﬂozin (1 mg mL1) after serial dilution. (b) UPLC
chromatogram of the Tradjenta® tablet extract in methanol containing linagliptin (5 mg mL1) after serial dilution. (c) UPLC chromatogram of the
Glucophage® tablet extract in methanol containing metformin hydrochloride (10 mg mL1) after serial dilution.

sampler and only ten micro liters was injected. A calibration
curve was obtained by plotting the area under the peak (AUP)
against concentration (C).
2.7.2. Assay of EGN, LGP and MET in bulk (accuracy), the
lab prepared mixtures, and the Jardiance®, Tradjenta®,
Glucophage®, Jentadueto®, Synjardy® and Glyxambi® tablets.
The procedure mentioned under 2.7.1. was repeated using
concentrations equivalent to 5, 10, 15, 20 and 25 mg mL1 EGN,
concentrations equivalent to 3, 6, 9, 12 and 15 mg mL1 LGP and

Table 3

Statistical comparison between the results of the proposed UPLC method and the reference method for LGP and MET

Statistical term

Reference method, LGP5

Mean
S.D.
%RSD
n
V
t (2.306)a
F (6.39)a

99.45
1.34
1.35
5
1.8

a

concentrations equivalent to 10, 30, 50, 70 and 90 mg mL1 MET.
Also diﬀerent ratios of EGN, LGP and MET were prepared using
the laboratory prepared mixtures. For the determination of
EGN, LGP and MET in the Jardiance®, Tradjenta®,
Glucophage®, Jentadueto®, Synjardy® and Glyxambi® tablets,
the sample solutions prepared as detailed under 2.6. were
serially diluted and then the procedure mentioned under 2.7.1.
was repeated. The concentrations of the mentioned drugs were
calculated using their specied calibration equations.

UPLC method,
LGP
98.88
1.06
1.07
5
1.12
0.75
1.61

Reference method, MET5
100.40
1.05
1.05
5
1.1

UPLC method,
MET
100.65
1.18
1.18
5
1.39
0.35
1.26

Figures in parentheses are the theoretical t and F values at p ¼ 0.05.
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2.7.3. Precision of the proposed method. Three diﬀerent
concentrations of EGN (16, 20 and 24 mg mL1), LGP (8, 10 and
12 mg mL1) and MET (40, 50 and 60 mg mL1) were analyzed
three times, within the same day, using the procedure
mentioned under 2.7.1. Also the mentioned concentrations
were analyzed on three successive days using the same
procedure.
2.7.4. Robustness of the chromatographic method. The
ow rate of the mobile phase was changed from 0.4 mL min1
to 0.38 mL min1 and 0.42 mL min1. The proportion of the
organic solvent in the mobile phase was changed by 1%.
Finally, the value of the pH of the phosphate buﬀer was varied
from 4.0 to 3.9 and 4.1.

3.

Results and discussion

3.1. Advantages of the newly proposed UPLC method
It is the rst method for simultaneous determination of EGN,
LGP and MET with possible application to six approved dosage
forms including EGN (Jardiance®), LGP (Tradjenta®), MET
(Glucophage®), LGP & MET (Jentadueto®), EGN & MET (Synjardy®), and EGN & LGP (Glyxambi®). Also, to the best of the
author’s knowledge, no published methods are available for
sensitive determination of EGN either alone or as part of
a combination in pharmaceutical dosage forms.
In addition, it is the rst method that applies UPLC for LGP
and MET rather than HPLC, with many associated advantages
such as that UPLC operates at much higher pressures. This ultra
pressure ensures the advantages of improved resolution and
fewer consumables. One of the key advantages is the resolution,
as dened by the peak shape. HPLC typically produces broad
peaks that skilled operators can characterize very well,
including peak heights and peak widths. Another important
advantage is a faster run time. The signicant reduction in
solvent use is another important advantage of UPLC. Not only
does the higher pressure system require less solvent, but shorter
run times also require less solvent. Moving from HPLC to UPLC
means higher resolution coupled with increased throughput
analysis, decreased solvent use, and decreased cost.

3.2. Method development for the chromatographic method
During the optimization process, several columns were tested
for the experiment, but the C18 column showed the best results
with good peak intensity, sharp peaks with enhanced resolution, and high throughput elution. Using a cyano column
reversed the elution with less resolution and less symmetric
peaks. Various mobile phase compositions, containing
diﬀerent ratios of organic and aqueous phases were tried in an
isocratic mode. Methanol was found to be the optimum for the
elution process. Besides, the use of diﬀerent buﬀers at diﬀerent
pH values was attempted along with the methanol. The pH
value of the buﬀer was adjusted to be 4.00 to ensure that its
value was below or above the pKa values of the studied drugs by
more than two, as the pKa of EGN is 12.6 and the pKa of MET is
12.4, while LGP has two pKa values which are 1.9 and 8.6.

This journal is © The Royal Society of Chemistry 2015

UV detection at 225 nm was selected according to the UV
spectra of the studied drugs and the phosphate buﬀer showed
the optimum conditioning at this wavelength rather than
acetate, formate or other buﬀers. Adjusting the ow rate to 0.4
mL min1 was crucial for the proposed method to enhance the
resolution between the three peaks. Applying a ow rate of more
than 0.4 increased the back pressure of the UPLC system to
more than 400 psi which is not favorable. The marked increase
in the column temperature to 50  C allowed greater symmetry of
the eluted peaks with less noise and less tailing, while an
increase of the column temperature to over 50  C was not
applicable in order to avoid thermal degradation of the processed samples.
3.3. System suitability tests for the UPLC method
System suitability tests were used to verify that the detection
sensitivity, resolution and reproducibility of the chromatographic system are adequate for the analysis to be done. The
resolution factor shows the accuracy of the quantitative analysis, it is specied to ensure that closely eluting compounds are
resolved from each other, the column eﬃciency is specied as
a system suitability requirement and is a measure of peak
sharpness, which is important for the detection of trace
compounds, while the tailing factor is a measure of peak
symmetry. Diﬀerent parameters aﬀecting the chromatographic
separation were studied, including the column eﬃciency
(number of theoretical plates), the tailing of the chromatographic peak, the peak resolution factor, and the %RSD of the
peak area and retention time of six injections, as shown in
Table 1.
3.4. Method validation
The method was validated according to ICH guidelines.26
3.4.1. Linearity. In this study, a linear relationship between
the area under the peak (AUP) and the component concentration (C) was obtained using six chosen concentrations for each
drug and the regression equations were then computed for the
chromatographic method. The linearity of the calibration
curves was validated by the high value of the correlation coefcient, acceptable values of the regression coeﬃcients, the
standard deviation of the slope and the standard deviation of
the intercept, as shown in Table 2.
3.4.2. Accuracy. The accuracy of the results was calculated
using the %recovery for 5 diﬀerent concentrations of each drug.
The results, including the mean of the recovery and the standard deviation, are shown in Table 2.
3.4.3. Precision.
3.4.3.1. Repeatability. Three concentrations of EGN (16, 20
and 24 mg mL1), three concentrations of LGP (8, 10 and 12 mg
mL1) and three concentrations of MET (40, 50 and 60 mg mL1)
were analyzed three times, within the same day, using the
procedure mentioned under 2.7. The %RSD was calculated and
found to be less than 2% using the three concentrations, as
shown in Table 2.
3.4.3.2. Intermediate precision. The above mentioned
concentrations were analyzed on three successive days using

RSC Adv., 2015, 5, 95703–95709 | 95707
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the procedure mentioned under 2.7. The %RSD was calculated
and the results are shown in Table 2.
3.4.4. Robustness of the chromatographic method. The
robustness was investigated by deliberately changing the chromatographic conditions. The most important parameter to be
studied was the resolution factor between the two peaks of MET
and LGP and also between the two peaks of LGP and EGN. The
ow rate of the mobile phase was changed from 0.4 mL min1
to 0.38 mL min1 and 0.42 mL min1, and the resolution factors
obtained were (2.08, 4.81), (1.98, 4.67) and (2.19, 4.94), respectively. Additionally, the proportion of methanol was changed
from 50% to 49% and 51%, and the resolution factors obtained
were (2.08, 4.81), (2.13, 4.69) and (2.16, 4.86), respectively.
Finally, the value of the pH of the phosphate buﬀer was varied
from 4.0 to 3.9 and 4.1, and the resolution factors obtained were
(2.08, 4.81), (1.90, 4.85) and (2.10, 4.97), respectively. There was
no signicant diﬀerence in the results obtained for all these
variations, indicating a good robustness of the proposed LC
method.
3.4.5. Specicity. Specicity is the ability of an analytical
method to measure the analyte response in the presence of
interference sources including other drugs or excipients. In the
present work, the specicity was checked by analyzing 5
diﬀerent concentrations of each drug in the presence of the
excipients of diﬀerent pharmaceutical dosage forms. The
results including the mean of the recovery and the standard
deviation are shown in Table 2.
3.4.6. Limit of detection and limit of quantication. The
limit of detection (LOD), which represents the concentration of
the analyte at a S/N ratio of 3.3, and the limit of quantication
(LOQ) at which the S/N ratio is 10 were determined and the
results are shown in Table 2. Low values of the LOD and LOQ
indicate sensitivity of the applied method for determination of
the mentioned drugs in tablets.
3.4.7. Pharmaceutical dosage forms & the standard addition technique. The proposed chromatographic method was
successfully applied to diﬀerent pharmaceutical dosage forms
and to check the validity of the proposed method, a standard
addition technique was applied by adding diﬀerent known
concentrations of the pure drug (2, 4 and 8 mg mL1 of EGN, 1, 2
and 4 mg mL1 of LGP and 10, 20 and 40 mg mL1 of MET) to
diﬀerent known concentrations of each drug product and the
procedures mentioned under 2.7.1. were adopted (Fig. 2 and 3).
The concentrations were calculated using the corresponding
regression equations in Table 2.
3.4.8. Statistical analysis. Statistical analysis of the results
obtained using the proposed method and the well established
HPLC reference method for the determination of LGP and MET5
was carried out using “SPSS statistical package version 11”.
Signicant diﬀerences between the reference method and the
described method were investigated using a t-test and F-test at
P ¼ 0.05, as shown in Table 3. The tests ascertained that there
was no signicant diﬀerence among the methods. No statistical
comparison was carried out for EGN as the proposed method is
the rst method for its determination either alone or as part of
a combination.
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4. Conclusion
The newly proposed method was proven to be simple, accurate,
precise and reproducible for the simultaneous determination of
EGN, LGP and MET in bulk and in the diﬀerent combinations of
their pharmaceutical dosage forms, in a reasonable run time
with high throughput analysis. The method was validated,
showing satisfactory data for all the parameters tested. The
developed UPLC method can be conveniently used by quality
control laboratories and has the advantages of a simple mobile
phase, saving time and a decreased cost due to less solvent
being used in UPLC.
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